Synthetic PET from CT improves diagnosis and prognosis for lung cancer: Proof of concept.
Turing test
generative AI
generative adversarial network
image synthesis
lung cancer
prognostic marker
radiogenomics
radiomics
screening
synthetic PET
Journal
Cell reports. Medicine
ISSN: 2666-3791
Titre abrégé: Cell Rep Med
Pays: United States
ID NLM: 101766894
Informations de publication
Date de publication:
04 Mar 2024
04 Mar 2024
Historique:
received:
01
02
2023
revised:
07
09
2023
accepted:
15
02
2024
medline:
13
3
2024
pubmed:
13
3
2024
entrez:
12
3
2024
Statut:
aheadofprint
Résumé
[
Identifiants
pubmed: 38471502
pii: S2666-3791(24)00107-1
doi: 10.1016/j.xcrm.2024.101463
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
101463Informations de copyright
Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests T.C. reports speaker fees and honoraria from The Society for Immunotherapy of Cancer, Bristol Myers Squibb, Roche, Medscape, and PeerView; having an advisory role or receiving consulting fees from AstraZeneca, Bristol Myers Squibb, EMD Serono, Merck & Co., Genentech, and Arrowhead Pharmaceuticals; and institutional research funding from AstraZeneca, Bristol Myers Squibb, and EMD Serono. L.Y. has grant support from Lantheus Inc. D.L.G. has served on scientific advisory committees for Menarini Ricerche, 4D Pharma, Onconova, and Eli Lilly and has received research support from Takeda, Astellas, NGM Biopharmaceuticals, Boehringer Ingelheim, and AstraZeneca. N.I.V. receives consulting fees from Sanofi, Regeneron, Oncocyte, and Eli Lilly and research funding from Mirati, outside the submitted work. J.D.H. is on the Scientific Advisory Board of Imagion Biosystems. J.Y.C. reports research funding from BMS-MDACC and Siemens Healthcare, and consultation fees from Legion Healthcare Partners. L.Y. has grant support from Lantheus Inc. M.C.B.G. has received research funding from Siemens Healthcare. I.W. has received honoraria from Genentech/Roche, AstraZeneca, Merck, Guardant Health, Flame, Novartis, Sanofi, Daiichi Sankyo, Dava Oncology, Amgen, GlaxoSmithKline, HTG Molecular, Jansen, Merus, Imagene, G1 Therapeutics, Abbvie, Catalyst Therapeutics, Genzyme, Regeneron, Oncocyte, Medscape, Platform Health, Pfizer, Physicians’ Education Resource, HPM Education, and Aptitute Health; additionally, I.W. has received research support from Genentech, Merck, Bristol-Myers Squibb, Medimmune, Adaptive, Adaptimmune, EMD Serono, Pfizer, Takeda, Amgen, Karus, Johnson & Johnson, Bayer, Iovance, 4D, Novartis, and Akoya. D.L.G. has served on scientific advisory committees for Menarini Ricerche, 4D Pharma, Onconova, and Eli Lilly and has received research support from Takeda, Astellas, NGM Biopharmaceuticals, Boehringer Ingelheim, and AstraZeneca. J.V.H. reports being on scientific advisory boards for AstraZeneca, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Eli Lilly, Novartis, Spectrum, EMD Serono, Sanofi, Takeda, Mirati Therapeutics, BMS, and Janssen Global Services; receiving research support from AstraZeneca, Takeda, Boehringer Ingelheim, and Spectrum; and receiving licensing fees from Spectrum. C.C.W. reports research support from Medical Imaging and Data Resource Center from NIBIB/University of Chicago and royalties from Elsevier. J.Z. reports serving on the consulting/advisory board of Bristol-Myers Squibb, AstraZeneca, Novartis, Johnson & Johnson, GenePlus, Innovent, Varian, and Catalyst, and receiving research grants to institution from Merck, Novartis, and Johnson & Johnson. J.W. reports research funding from Siemens Healthcare.